ArticleFrontiers in oncology2024
Case report: High-grade hidradenocarcinoma of the chest wall with insights from
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenocarcinoma (HAC) is a rare neoplasm that typically occurs in the head and neck region but seldom affects the chest wall. Histopathology and immunohistochemistry remain essential for diagnosing HAC, although their clinical utility in determining metastasis can be limited. Given the pathological rarity and histopathological heterogeneity of HAC, we report a case demonstrating the utility of positron emission tomography/computed tomography (PET/CT) combined with immunohistochemical examination for the accurate diagnosis and staging of HAC. An 84-year-old woman presented to our hospital with a right chest wall and axillary mass. A pathological examination was performed, which revealed a malignancy of epithelial origin. The immunohistochemical examination confirmed a high-grade hidradenocarcinoma. Subsequently, PET/CT examination showed significant hypermetabolism in the right chest wall and its ipsilateral axillary and subclavian lymph nodes. Combined with pathological findings, these results confirmed metastatic hidradenocarcinoma, leading to a TNM classification of T2N3M (stage IV). A literature review revealed that HAC rarely occurs in the chest wall but tends to metastasize. However, the prognosis is favorable, especially with early diagnosis and surgical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.